Post-operative Pain Therapeutics Market (Drug Class: Opioids, NSAIDS, Local Anesthetics, Tricyclic Antidepressants, Antiepileptic Drugs, and Others; Route of Administration: Oral, Intramuscular, Intravenous, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030

The global Post-operative Pain Therapeutics market gathered revenue around USD 12.1 Bn billion in 2021 and market is set to grow USD 20.6 billion by the end of 2030 and is estimated to expand at a modest CAGR of 6.2% during the prediction period 2022 to 2030.

Growth Factors:

Increase in surgical procedures followed by post-surgical problems is anticipated to drive the global post-operative pain therapeutics market during the forecast period. Key players focus on manufacturing of cost-effective post-operative pain therapeutics. The global post-operative pain therapeutics market is expected to be driven by increase in the number of elderly patients, rise in prevalence of diseases, surge in number of regulatory approvals, and demand for post-operative pain therapeutics.

Asia Pacific held major share of the global post-operative pain therapeutics market in 2020 due to the presence of large number of key players, rise in demand for post-operative pain therapeutics, and increase in elderly patients. The post-operative pain therapeutics market in Asia Pacific is expected to expand at a CAGR of 6.7% from 2022 to 2030 owing to surge in number of elderly patients and increase in product approvals from regulatory authorities. This, in turn, is likely to drive the demand for post-operative pain therapeutics in emerging markets such as India and China.

Report Scope of the Post-operative Pain Therapeutics Market

Report Coverage

Details

Market Size

US$ 20.6 Billion by 2030

Growth Rate

CAGR of 6.2% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Drug Class, Route of Administration, Distribution Channel and Region,

Companies Mentioned

 Allergan plc, Bayer AG, Camarus, Eli Lilly & Company, Egalet Corporation, Endo International plc, Janssen Pharmaceuticals, Inc., GlaxoSmithKline plc, Mallinckrodt Pharmaceuticals, Mylan N.V., Novartis AG, Pacira Pharmaceuticals, Inc., Pfizer, Inc., Purdue Pharma L.P, Teva Pharmaceutical Industries Ltd., and Trevena, Inc..

Advent of New Technology to Drive Global Market

The postoperative pain therapeutics market has witnessed significant investments by multinational corporates in the past few years. These business conglomerates have invested in companies operating in the postoperative pain therapeutics market. Camurus AB announced that the regulatory agency of Australia, the Therapeutic Goods Administration (TGA), approved key label updates to Buvidal Weekly and Buvidal Monthly (buprenorphine) modified-release solutions for injection for the treatment of opioid dependence.

Pacira BioSciences, Inc. received the FDA approval for its supplemental new drug application (sNDA) to broaden the use of EXPAREL (bupivacaine liposome injectable suspension) to include administration via interscalene brachial plexus block to produce postsurgical regional analgesia. Trevena announced FDA approval for OLINVYK (oliceridine) injection. OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic.

Pfizer, Inc. focuses on the development of biosimilar formulations in key therapeutic areas, owing to its potential to improve patient care by extending access to high quality, effective, and targeted treatment for multiple serious and chronic diseases.

Opioids Dominated Post-operative Pain Therapeutics Market

In terms of drug class, the global post-operative pain therapeutics market has been classified into opioids, NSAIDS, local anesthetics, tricyclic antidepressants, antiepileptic drugs, and others. The opioids segment dominated the global post-operative pain therapeutics market in 2020 and the trend is projected to continue during the forecast period. Increase in demand for opioids is expected to drive the segment over the next few years.

Oral Preferred Route of Administration

In terms of route of administration, the global post-operative pain therapeutics market has been categorized into oral, intramuscular, intravenous, and others. The oral segment dominated the global post-operative pain therapeutics market in 2020, and the trend is projected to continue during the forecast period.

Hospital Pharmacies to be Lucrative Distribution Channel

In terms of distribution channel, the global post-operative pain therapeutics market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment held major share of the global post-operative pain therapeutics market in 2020.

Asia Pacific to Lead Global Market

In terms of region, the global post-operative pain therapeutics market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Asia Pacific is projected to account for leading share of the global post-operative pain therapeutics market during the forecast period, owing to increase in number of patients suffering from chronic diseases in hospitals. The post-operative pain therapeutics market in Asia Pacific is projected to grow at a rapid pace in the next few years. India, China, and South Korea are expected to be lucrative markets in the near future.

Some of the prominent players in the Post-operative Pain Therapeutics Market include:

  • Allergan plc
  • Bayer AG
  • Camarus
  • Eli Lilly & Company
  • Egalet Corporation
  • Endo International plc
  • Janssen Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Mallinckrodt Pharmaceuticals
  • Mylan N.V.
  • Novartis AG
  • Pacira Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Purdue Pharma L.P
  • Teva Pharmaceutical Industries Ltd.
  • Trevena, Inc.

Segments Covered in the Report

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:

Global Post-operative Pain Therapeutics Market: Segmentation

  • Post-operative Pain Therapeutics Market, by Drug Class
    • Opioids
    • NSAIDS
    • Local Anesthetics
    • Tricyclic Antidepressants
    • Antiepileptic Drugs
    • Others
  • Post-operative Pain Therapeutics Market, by Route of Administration
    • Oral
    • Intramuscular
    • Intravenous
    • Others
  • Post-operative Pain Therapeutics Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Points Covered in Post-operative Pain Therapeutics Market Study:

  • Growth of Post-operative Pain Therapeutics in 2022
  • Market Estimates and Forecasts (2017-2030)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •  Recommendation on Key Winning Strategies
  •  COVID-19 Impact on Demand for Post-operative Pain Therapeutics and How to Navigate
  •  Key Product Innovations and Regulatory Climate
  •  Post-operative Pain Therapeutics Consumption Analysis
  •  Post-operative Pain Therapeutics Production Analysis
  •  Post-operative Pain Therapeutics and Management

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Postoperative Pain Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Postoperative Pain Therapeutics Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)

    5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    5.3. Pipeline Analysis

    5.4. Regulatory Scenario, by Region/globally

    5.5. Healthcare Industry Overview

6. Global Postoperative Pain Therapeutics Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2030

        6.3.1. Opioids

        6.3.2. NSAIDS

        6.3.3. Tricyclic Antidepressants

        6.3.4. Antiepileptic Drugs

        6.3.5. Local Anesthetics

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Postoperative Pain Therapeutics Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2030

        7.3.1. Oral

        7.3.2. Intravenous

        7.3.3. Intramuscular

        7.3.4. Others

    7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Postoperative Pain Therapeutics Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2030

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

        8.3.4. Others

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Postoperative Pain Therapeutics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness Analysis, by Region

10. North America Postoperative Pain Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2030

        10.2.1. Opioids

        10.2.2. NSAIDS

        10.2.3. Tricyclic Antidepressants

        10.2.4. Antiepileptic Drugs

        10.2.5. Local Anesthetics

        10.2.6. Others

    10.3. Market Value Forecast, by Route of Administration, 2017–2030

        10.3.1. Oral

        10.3.2. Intravenous

        10.3.3. Intramuscular

        10.3.4. Others

    10.4. Market Value Forecast, by Distribution Channel, 2017–2030

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

        10.4.4. Others

    10.5. Market Value Forecast, by Country, 2017–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Route of Administration

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Postoperative Pain Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2030

        11.2.1. Opioids

        11.2.2. NSAIDS

        11.2.3. Tricyclic Antidepressants

        11.2.4. Antiepileptic Drugs

        11.2.5. Local Anesthetics

        11.2.6. Others

    11.3. Market Value Forecast, by Route of Administration, 2017–2030

        11.3.1. Oral

        11.3.2. Intravenous

        11.3.3. Intramuscular

        11.3.4. Others

    11.4. Market Value Forecast, by Distribution Channel, 2017–2030

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

        11.4.4. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        11.5.1. U.K.

        11.5.2. Germany

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Route of Administration

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Postoperative Pain Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2030

        12.2.1. Opioids

        12.2.2. NSAIDS

        12.2.3. Tricyclic Antidepressants

        12.2.4. Antiepileptic Drugs

        12.2.5. Local Anesthetics

        12.2.6. Others

    12.3. Market Value Forecast By Route of Administration, 2017–2030

        12.3.1. Oral

        12.3.2. Intravenous

        12.3.3. Intramuscular

        12.3.4. Others

    12.4. Market Value Forecast By Distribution Channel, 2017–2030

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

        12.4.4. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        12.5.1. China

        12.5.2. India

        12.5.3. Japan

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Postoperative Pain Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast By Drug Class, 2017–2030

        13.2.1. Opioids

        13.2.2. NSAIDS

        13.2.3. Tricyclic Antidepressants

        13.2.4. Antiepileptic Drugs

        13.2.5. Local Anesthetics

        13.2.6. Others

    13.3. Market Value Forecast, by Route of Administration, 2017–2030

        13.3.1. Oral

        13.3.2. Intravenous

        13.3.3. Intramuscular

        13.3.4. Others

    13.4. Market Value Forecast, by Distribution Channel, 2017–2030

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

        13.4.4. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Postoperative Pain Therapeutics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2030

        14.2.1. Opioids

        14.2.2. NSAIDS

        14.2.3. Tricyclic Antidepressants

        14.2.4. Antiepileptic Drugs

        14.2.5. Local Anesthetics

        14.2.6. Others

    14.3. Market Value Forecast, by Route of Administration, 2017–2030

        14.3.1. Oral

        14.3.2. Intravenous

        14.3.3. Intramuscular

        14.3.4. Others

    14.4. Market Value Forecast, by Distribution Channel, 2017–2030

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

        14.4.4. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix

    15.2. Market Share Analysis, by Company, 2020

    15.3. Competitive Business Strategies

    15.4. Company Profiles

        15.4.1. Mallinckrodt Pharmaceuticals

            15.4.1.1. Company Description

            15.4.1.2. Business Overview

            15.4.1.3. Financial Overview

            15.4.1.4. SWOT Analysis

        15.4.2. Pfizer, Inc.

            15.4.2.1. Company Description

            15.4.2.2. Business Overview

            15.4.2.3. Financial Overview

            15.4.2.4. SWOT Analysis

        15.4.3. Novartis AG

            15.4.3.1. Company Description

            15.4.3.2. Business Overview

            15.4.3.3. Financial Overview

            15.4.3.4. SWOT Analysis

        15.4.4. Eli Lilly and Company

            15.4.4.1. Company Description

            15.4.4.2. Business Overview

            15.4.4.3. Financial Overview

            15.4.4.4. SWOT Analysis

        15.4.5. Teva Pharmaceutical Industries Ltd.

            15.4.5.1. Company Description

            15.4.5.2. Business Overview

            15.4.5.3. Financial Overview

            15.4.5.4. SWOT Analysis

        15.4.6. Camurus AB

            15.4.6.1. Company Description

            15.4.6.2. Business Overview

            15.4.6.3. Financial Overview

            15.4.6.4. SWOT Analysis

        15.4.7. Bayer AG

            15.4.7.1. Company Description

            15.4.7.2. Business Overview

            15.4.7.3. Financial Overview

            15.4.7.4. SWOT Analysis

        15.4.8. Pacira BioSciences, Inc.

            15.4.8.1. Company Description

            15.4.8.2. Business Overview

            15.4.8.3. Financial Overview

            15.4.8.4. SWOT Analysis

        15.4.9. Trevena, Inc.

            15.4.9.1. Company Description

            15.4.9.2. Business Overview

            15.4.9.3. Financial Overview

            15.4.9.4. SWOT Analysis

        15.4.10. Heron Therapeutics, Inc

            15.4.10.1. Company Description

            15.4.10.2. Business Overview

            15.4.10.3. Financial Overview

            15.4.10.4. SWOT Analysis

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers